Baker McKenzie has advised the shareholders of Swiss Cardio Technologies AG (“Swiss Cardio Technologies”), a medical company specializing in cardiovascular surgery solutions, on the sale of all their shares to Abacus Medicine Group. Founded in Denmark in 2004, Abacus Medicine Group is a leading pharmaceutical company focused on the parallel import of medicines to enhance access and affordability.
Swiss Cardio Technologies AG, established by renowned cardiovascular surgeons from the University of Berne, developed Cardioplexol®, an innovative cardioplegia solution used to safely arrest the heart during complex surgical procedures such as bypass operations and aortic repairs. The transaction is expected to accelerate international commercialization and expansion of Cardioplexol®, leveraging Abacus' extensive global network alongside Swiss Cardio Technologies’ relationships in cardiothoracic surgery.
Baker McKenzie advised the shareholders of Swiss Cardio Technologies on all legal aspects of the transaction.
Zurich-based partners Alexander Fischer (M&A) and Julia Schieber (M&A, Healthcare & Sciences) led the team, which consisted of the following: Matthias Trautmann (partner, M&A), Hesam Mirzai (associate, M&A) as well as trainee lawyers Elena Mani and Grégory Sarbach.
About Swiss Cardio Technologies AG
Swiss Cardio Technologies was founded by a group of cardiovascular surgery specialists in 2008. Following more than a decade of development, clinical trials and regulatory approval, the company began commercial activities in Switzerland in 2023, with ambitions to expand further into Europe and globally.
For more information, visit: www.swisscardiotech.com
About Abacus Medicine Group
The Abacus Medicine Group contributes to global healthcare by providing better access to medicines. With a workforce of more than 1,500 employees, the group generated revenue of EUR 1,487 million from sales across 35 countries in 2024. Recognized for its consistent profitable growth, Abacus continues to invest in people to remain an employer of choice, while also advancing scalable digital excellence.
For more information, visit: www.abacusmedicinegroup.com and www.abacusmedicinepharmaservices.com